✦ LIBER ✦

Patients with only 1 positive hormone receptor have increased locoregional recurrence compared with patients with estrogen receptor-positive progesterone receptor-positive disease in very early stage breast cancer

✍ Scribed by Jeffrey M. Albert; Ana M. Gonzalez-Angulo; Merih Guray; Aysegul Sahin; Welela Tereffe; Wendy A. Woodward; Eric A. Strom; Kelly K. Hunt; Susan L. Tucker; Thomas A. Buchholz

Publisher: John Wiley and Sons
Year: 2010
Tongue: English
Weight: 234 KB
Volume: 117
Category: Article
ISSN: 0008-543X
DOI: 10.1002/cncr.25694

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Benefit and projected cost-effectiveness

Benefit and projected cost-effectiveness of anastrozole versus tamoxifen as initial adjuvant therapy for patients with early-stage estrogen receptor–positive breast cancer

✍ Bruce E. Hillner 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 125 KB 👁 1 views

## Abstract ## BACKGROUND Women who have estrogen receptor (ER)‐positive disease with postmenopausal onset and who receive tamoxifen as standard adjuvant treatment constitute the largest subgroup of patients with breast cancer. Recent data from the ATAC (‘Arimidex, Tamoxifen Alone or in Combinatio